928 related articles for article (PubMed ID: 14510627)
1. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
4. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
5. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
6. Role of anti-interleukin-2 receptor antibodies in kidney transplantation.
Cibrik DM; Kaplan B; Meier-Kriesche HU
BioDrugs; 2001; 15(10):655-66. PubMed ID: 11604047
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
Wiseman LR; Faulds D
Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
[TBL] [Abstract][Full Text] [Related]
9. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
Ahsan N; Holman MJ; Jarowenko MV; Razzaque MS; Yang HC
Am J Transplant; 2002 Jul; 2(6):568-73. PubMed ID: 12118902
[TBL] [Abstract][Full Text] [Related]
10. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
Nashan B
BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
[TBL] [Abstract][Full Text] [Related]
11. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
12. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
13. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
14. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
[TBL] [Abstract][Full Text] [Related]
15. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab.
Mottershead M; Neuberger J
Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
[TBL] [Abstract][Full Text] [Related]
18. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab: a review of its use in the management of organ transplantation.
Carswell CI; Plosker GL; Wagstaff AJ
BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149
[TBL] [Abstract][Full Text] [Related]
20. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
